To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 15, 2017

Today's Rundown

Featured Story

Turnstone Biologics nabs Bristol-Myers R&D exec as new research chief

Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D. Burgess, who had been at BMS as its SVP, head of exploratory clinical and translational research since 2013, has jumped ship to the early-stage startup, which is focused on reviving the fortunes of research into oncolytic viruses and cancer vaccines.

Top Stories

Acorda slumps on safety fears for Parkinson’s drug tozadenant

Shares in Acorda Therapeutics are on the slide following the news that the company’s Parkinson’s drug tozadenant has been linked to a serious and potentially fatal side effect.

Sanofi, Novo back rare disease startup Inozyme in $49M round

Using tech licensed from Yale University and with a string of biopharma executives and Big Pharma venture backers, Inozyme Pharma has emerged from stealth with $49 million and a mission.

[Sponsored] Looking Toward Abuse Deterrent Opioids

The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results for patients.

Genentech doubles down on Arvinas, swelling deal to $650M

Genentech has doubled the size of its alliance with Arvinas, moving the potential value of the pact up above $650 million. The expansion of the deal gives the Roche subsidiary the chance to use Arvinas’ protein degradation technology against additional disease targets.

Germano lands spot on The Medicines Company’s board

The Medicines Company has tweaked its board, bringing former Pfizer executive Geno Germano in as an independent director and expanding Fred Eshelman’s role. Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company.

Acquisitive Quotient buys CDMO Pharmaterials, reveals new identity

After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase.

Resources

[Whitepaper] Accessing Scientific Literature Doesn’t Have To Be Like Scaling A Mountain

SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Whitepaper] eClinical Landscape Study from Tufts Center for the Study of Drug Development

See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges.

[Whitepaper] Modernize Quality Management

Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control.

[Whitepaper] DSM Looks to Challenge Traditional Stent Graft Materials with its Dyneema Purity® Membrane Edit

Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases.

[Whitepaper] Meeting the Challenge of Appropriate Safety Report Distribution

As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution.

[Webinar] Discover tested and proven solutions to manage territory vacancies

December 5, 2017 | 2pm EST / 11am PST

Join this webinar to learn methods that maintain and build sales momentum despite turnover.

[Whitepaper] Veeva 2017 Annual CRO Report: CROs lead the drive to a unified clinical model

CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.